Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Lupin Pharma
Lupin Pharma
Activities:
Manufacturing
Ingredients
Research & Development
X
LinkedIn
Trending Articles
How advanced technologies are unlocking the future of drug manufacturing
As the drug production landscape changes, it opens the door to pursue hybrid opportunities that push the boundaries of technological advancement in the field, reports Jon...
Actylis and Novo Nordisk Pharmatech partner for the distribution of benzalkonium chloride
The two companies aim to expand the distribution of benzalkonium chloride within Europe
Upperton opens novel development and GMP manufacturing facility
The novel 50,000 sqft development and GMP manufacturing facility in Nottingham contains ten GMP manufacturing suites, quality control laboratories and formulation development...
Astellas begins construction of manufacturing site in Tralee
600 construction jobs and 100 specialised engineering, science and technology roles will be created from the project
Policy vacuum risks UK becoming a medicines supply backwater
The UK becoming a "backwater" supply marker could jeopardise £18bn of NHS savings from newly off-patented drugs during the next five years
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Drug Delivery
Aptar and Lupin to launch India’s first smart device for metered-dose inhalers
ADHERO is designed to help patients with chronic respiratory diseases track their MDI usage
Finance
Neopharma subsidiary buys Japanese injectables business
Indian pharma Lupin will also sell all related assets in Japan to Neo ALA
Lupin looks to compete with Sun Pharma in Japanese market
Wholly-owned Japanese subsidiary, Kyowa, intends to set up a manufacturing plant at Tottori, Japan, as part of expansion plans in the country
Regulatory
Indian pricing authority to address overcharging by pharma companies
NPPA has decided to chase drug majors for defaulting on penalties that have been imposed for overcharging consumers for medicines
Regulatory
Several large Indian pharma companies under US FDA scrutiny
Recent regulatory action by the FDA on leading Indian firms has affected the country's exports, according to Chairman of Dr. Reddy's Laboratories
Pharmaceutical
Lupin set to launch generic version of Valeant diabetes drug Glumetza
The Indian firm has a 180-day exclusivity for the product
Pharmaceutical
Indian generic manufacturers aim to enter the Japanese market
The penetration of generic drugs in Japan is a little more than 30% compared with more 80% in the US market
Subscribe now